The last clinical trials for NHL

Non-Hodgkin’s lymphoma (NHL) is a type of cancer that originates in the lymphatic system, part of the body’s immune system.In NHL, abnormal lymphocytes – a type of white blood cell – begin to grow uncontrollably and form tumours in lymph nodes or other tissues. With more than ۶۰ distinct subtypes characterised by abnormal lymphoid cells at different stages of differentiation. NHL can affect people of all ages, but it is more commonly diagnosed in older adults. B-cell lymphomas, accounting for approximately ۸۵% of NHL cases in the United States, predominantly affect individuals aged ۶۰ years and older.Symptoms of NHL can include swollen lymph nodes, fever, night sweats, unexplained weight loss and fatigue. Treatment for NHL may involve chemotherapy, radiation therapy, immunotherapy, targeted therapy or stem cell transplant, depending on the subtype and stage of the disease. Early diagnosis and appropriate treatment are essential for managing NHL and improving outcomes. Recent clinical trials in non-Hodgkin lymphoma (NHL) have seen a significant increase in activity, particularly in ۲۰۲۳, with ۴۷۱ trials reported, marking a rebound from a slight decline in ۲۰۲۲. The majority of these trials focus on Phase II studies, which evaluate the efficacy and safety of new treatments in larger patient groups. Key Recent Trials and Developments: ۱. ATG-۱۰۱ Study: This Phase I trial is currently assessing the safety and efficacy of ATG-۱۰۱ in patients with advanced solid tumors and mature B-cell NHL. It involves a multicenter approach and includes both a dose escalation and expansion phase. ۲. Combination Therapies: Trials are ongoing to evaluate the effectiveness of combining drugs such as mosunetuzumab or glofitamab with CC-۲۲۰ and CC-۹۹۲۸۲ for treating B-cell NHL. These studies aim to assess safety, efficacy, and pharmacokinetics in adult participants. ۳. Epcoritamab Trials: Another notable study is examining the use of epcoritamab, either alone or in combination with other therapies, to treat B-cell NHL. This trial aims to determine the optimal dosing and treatment regimens for various patient subgroups. ۴. Innovative Drug Combinations: Research continues into new combinations of existing therapies. For instance, lenalidomide combined with rituximab has shown promising results in treating frontline and relapsed/refractory NHL. ۵. Targeted Therapies: Recent advancements include the exploration of targeted treatments that focus on specific genetic markers in lymphoma cells. This includes ongoing research into drugs like venetoclax and loncastuximab, which have shown efficacy in specific lymphoma subtypes. The landscape of clinical trials for Non-Hodgkin's Lymphoma is rapidly evolving, with a focus on innovative treatments and personalized medicine approaches. The increased number of trials reflects a robust interest in finding effective therapies that can improve patient outcomes and potentially lead to cures for various subtypes of this complex disease.

کلیدواژه ها:

Non-Hodgkin’s lymphoma ، Targeted Therapies ، Combination Treatments ، lymphomas